Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tessa McSpadden"'
Autor:
Anthony D. Elias, Alyse W. Staley, Monica Fornier, Gregory A. Vidal, Vida Alami, Sharon Sams, Nicole S. Spoelstra, Andrew Goodspeed, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathryn L. Zolman, Tessa McSpadden, Kimberly R. Jordan, Jill E. Slansky, Virginia F. Borges, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tu
Externí odkaz:
https://doaj.org/article/564ac0eba47340f495698648097af1b7
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Anthony D. Elias, Alyse Staley, Monica Fornier, Gregory A. Vidal, Sharon Sams, Nicole Spoelstra, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Kathryn Zolman, Stephanie Biller, Vida Alami, Tessa McSpadden, Virginia Borges, Lyndsey S. Crump, Dexiang Gao, Jennifer K. Richer
Publikováno v:
Cancer Research. 83:CT144-CT144
Background: Most estrogen receptor alpha positive (ER+) breast cancers (BCs) express androgen receptor (AR) protein, but its function is unclear. High AR relative to ER is associated with endocrine resistance. This randomized phase II trial of neoadj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85340548b90a85832ba4e5ded420688f
https://doi.org/10.1158/1538-7445.am2023-ct144
https://doi.org/10.1158/1538-7445.am2023-ct144
Autor:
Dexiang Gao, Tessa McSpadden, Sharon Sams, Anthony D. Elias, Virginia F. Borges, Julia Wulfkuhle, Anosheh Afghahi, Emanuel F. Petricoin, Jose I. Mayordomo, Stephanie Armstead, Jennifer R. Diamond, Nicole Spoelsta, Gregory A. Vidal, Elena Shagisultanova, Peter Kabos, Jennifer K. Richer, Lisa Carter, Monica Fournier, Gloria Crawford, Alyse Winchester, Kathryn Zolman
Publikováno v:
Cancer Research. 81:PS12-06
Background: Almost all ER+ breast cancers express androgen receptor (AR), but its function is uncertain. AR expression is associated with more indolent tumors, however high AR expression relative to ER is associated with endocrine resistance, and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5e95c71bea853f203f093c045b5b55
https://doi.org/10.1158/1538-7445.sabcs20-ps12-06
https://doi.org/10.1158/1538-7445.sabcs20-ps12-06
Autor:
Jose I. Mayordomo, Gloria Crawford, Virginia F. Borges, Gregory A. Vidal, Alyse Winchester, Kathryn Zolman, Elena Shagisultanova, Stephanie Armstead, Jennifer K. Richer, Lisa Carter, Dexiang Gao, Anosheh Afghahi, Sharon Sams, Emanuel F. Petricoin, Tessa McSpadden, Peter Kabos, Nicole Spoelsta, Anthony D. Elias, Julia Wulfkuhle, Jennifer R. Diamond
Publikováno v:
Cancer Research. 81:PS12-14
Up to 91% of ER+ breast cancers express androgen receptor (AR), but its function is uncertain. Although AR expression is associated with more indolent tumors, high AR expression relative to ER is associated with endocrine resistance, and in the absen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd471d9d872afdb58daaf362329e009b
https://doi.org/10.1158/1538-7445.sabcs20-ps12-14
https://doi.org/10.1158/1538-7445.sabcs20-ps12-14
Autor:
Gloria Crawford, Julia D. Wulfkuhle, Tessa McSpadden, Gregory A. Vidal, Jennifer K. Richer, Sharon Sams, Elena Shagisultanova, Anosheh Afghahi, Jose I. Mayordomo, Virginia F. Borges, Dexiang Gao, Nicole S. Spoelstra, Alyse Winchester, Peter Kabos, Emanuel F. Petricoin, Anthony D. Elias, Jennifer R. Diamond
Publikováno v:
Cancer Research. 81:2867-2867
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) are unclear. While AR is associated with more indolent primary tumors, high AR rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecfaebd7a5483242a4643ebed443feb9
https://doi.org/10.1158/1538-7445.am2021-2867
https://doi.org/10.1158/1538-7445.am2021-2867
Autor:
Emma Barrett, Gina Fernetich, Tara Baetz, Renae Chavira, Tessa McSpadden, Kari Guthrie, Stephen Chia, Rashmi Krishna Murthy, Stacy L. Moulder, Virginia F. Borges
Publikováno v:
Clinical Cancer Research. 23:3529-3536
Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD, pharmacokinetics (PK) and antitumor activity of ONT-380 in HER2-positive advanced solid tumors, with an expansion cohort of patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::402550103083b974e694f8f234784f1f
https://doi.org/10.1158/1078-0432.ccr-16-1496
https://doi.org/10.1158/1078-0432.ccr-16-1496
Autor:
Elena Shagisultanova, Lajos Pusztai, Peter Kabos, Virginia F. Borges, Tessa McSpadden, Michelle Borakove, Jennifer R. Diamond, Ruth O'Regan, T Shedin, Pavani Chalasani, Alison Stopeck, Ursa Brown-Glaberman, William J. Gradishar
Publikováno v:
Cancer Research. 78:OT1-03
Breast cancers overexpressing HER2-oncogene and hormone receptors (HR) represent therapeutic challenge because of a bi-directional cross-talk between HR and HER2 pathways leading to tumor progression and drug resistance. There is a strong rationale f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::672e798b8fa717a1563b2e315f41782a
https://doi.org/10.1158/1538-7445.sabcs17-ot1-03-06
https://doi.org/10.1158/1538-7445.sabcs17-ot1-03-06
Autor:
Peter Kabos, William J. Gradishar, Tessa McSpadden, Pavani Chalasani, Dexiang Gao, Andrew Brenner, Elena Shagisultanova, Ursa Brown-Glaberman, Virginia F. Borges, Alison Stopeck
Publikováno v:
Journal of Clinical Oncology. 37:1029-1029
1029 Background: Based on preclinical synergy, we are conducting a phase IB/II clinical trial of tucatinib (HER2 small molecule inhibitor, T), palbociclib (CDK4/6 inhibitor, P) and letrozole (aromatase inhibitor, L) in HR+/HER2+ metastatic breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::608075bcfb08710038bb0d2a5d3dfae1
https://doi.org/10.1200/jco.2019.37.15_suppl.1029
https://doi.org/10.1200/jco.2019.37.15_suppl.1029
Autor:
Gina Fernetich, Tara Baetz, Virginia F. Borges, Tessa McSpadden, Jennifer Garrus, Steven K.L Chia, Susan D'Aloisio, Bessie Sajan, Stacy L. Moulder, Emma Barrett, Kari Guthrie, Renae Chavira
Publikováno v:
Molecular Cancer Research. 11:A050-A050
Background: Overexpression of HER2 occurs in ~25% of breast cancers. Despite the treatment successes achieved to date, improved clinical outcomes remain needed, including prevention and treatment of CNS metastases. Small-molecule HER2 inhibitors may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b0d6a2d86e05194c9b40688e5ce6dd
https://doi.org/10.1158/1557-3125.advbc-a050
https://doi.org/10.1158/1557-3125.advbc-a050